Fig. 8

OTX008 alone and OTX008/nab-paclitaxel exert antitumor effect on the GC xenograft model. A The cytotoxicity of nab-paclitaxel alone, the AKT inhibitor MK2206 alone, and the combination of nab-paclitaxel and MK2206 in AGS cells. B The cytotoxicity of nab-paclitaxel alone, the ERK inhibitor U0126 alone, and the combination of nab-paclitaxel and U0126 in AGS cells. C The cytotoxicity of nab-paclitaxel alone, the GAL-1 inhibitor OTX008 alone, and the combination of nab-paclitaxel and OTX008 in AGS cells. D-F The cytotoxicity of nab-paclitaxel alone, the GAL-1 inhibitor OTX008 alone, and the combination of nab-paclitaxel and OTX008 in AGS, MGC-803 and HGC-27 cells. G The combination index (C.I.) of the treatment with the combination of OTX008 and nab-paclitaxel was calculated using CalcuSyn software. C.I. < 0.9 indicates synergism, C.I. = 0.9–1.10 indicates an additive interaction, and C.I. > 1.1 indicates antagonism. H Phospho-ERK and phospho-AKT levels were reduced by the combination treatment (OTX008 and n nab-paclitaxel). I Schematic showing the results of the in vivo experiment. ZFP64-overexpressing HGC27 cells (1 × 10⁶) were subcutaneously injected into athymic nude mice (8 mice/group) or humanized mice (5 mice/group). After 2 weeks, mice were treated with vehicle, nab-paclitaxel, OTX008 or OTX008/nab-paclitaxel. After euthanasia, the tumor tissues collected from humanized mice were subjected to immunohistochemical staining. J Representative images of tumors from nude mice after various treatments. K-L Tumor growth curves and tumor weights of each group. M-N Tumor growth curves and tumor weights of humanized mice in different groups. O Representative images of IHC staining showing tumor-infiltrating CD8+ lymphocytes, IFN-γ and perforin in serial sections of tumors from humanized mice. Data are presented as the means ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.005